WO2016209881A1 - Formulations de soin buccal contenant des copolymères - Google Patents
Formulations de soin buccal contenant des copolymères Download PDFInfo
- Publication number
- WO2016209881A1 WO2016209881A1 PCT/US2016/038644 US2016038644W WO2016209881A1 WO 2016209881 A1 WO2016209881 A1 WO 2016209881A1 US 2016038644 W US2016038644 W US 2016038644W WO 2016209881 A1 WO2016209881 A1 WO 2016209881A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- weight
- oral care
- copolymer particles
- acid
- copolymer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
- A61K8/8141—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
- A61K8/8152—Homopolymers or copolymers of esters, e.g. (meth)acrylic acid esters; Compositions of derivatives of such polymers
Definitions
- This invention relates generally to copolymers that are useful in oral care formulations.
- the oral care formulations contain copolymer particles bearing phosphorus acid groups.
- Oral care compositions contain a variety of additives that provide a wide array of benefits to the composition. Toothpastes, for example, contain additives that offer protection from acid dissolution of tooth enamel. Bacteria thrive on sugar and produce high acid levels in oral settings that can erode tooth enamel, leading to the formation of dental caries. Currently, fluoride containing compositions are widely used to protect against acid erosion of tooth enamel and to prevent the formation of dental caries. Conventional fluoride containing compositions, however, lack the efficacy to provide long term enamel protection, for example, lasting 8 to 12 hours after deposition.
- One aspect of the invention provides an oral care composition
- an oral care composition comprising (a) 0.001 to 50 weight % copolymer particles dispersed in an aqueous medium, based on the weight of the composition, wherein the copolymer particles comprise polymerized units derived from (i) 0.1 to 20 weight % of phosphorus acid monomers, and (ii) 80 to 99.9 weight % of comonomers, and (b) an orally acceptable carrier.
- the invention provides a method for protecting tooth enamel from acid erosion comprising applying to the tooth enamel an oral care composition comprising (a) 0.001 to 50 weight % copolymer particles dispersed in an aqueous medium, based on the weight of the composition, wherein the copolymer particles comprise polymerized units derived from (i) 0.1 to 20 weight % of phosphorus acid monomers, and (ii) 80 to 99.9 weight % of comonomers, and (b) an orally acceptable carrier.
- copolymer particles comprising polymerized units derived from phosphorus acid monomers provide superior fluoride deposition and adhesion properties to prevent erosion of calcium on teeth, while also being biologically acceptable and readily applicable. Accordingly, the present invention provides in one aspect an oral care composition comprising copolymer particles dispersed in an aqueous medium comprising polymerized units of phosphorus acid monomers and comonomers, and an orally acceptable carrier.
- oral care compositions is intended to refer to compositions suitable for preventing or treating a disease or condition of the oral cavity, including, for example dentifrices, toothpastes, tooth gels, dental creams, mouthwashes, mouth rinses, chewing gums, denture adhesives, or portable dosage articles including, for example, a lozenge, a mint, bead, wafer, liquid formulated for oral application in a small portable nebulizer (spray bottle), liquid formulated for oral application in a small portable drop -generating bottle, or a soft pliable tablet (“chewie”).
- the oral care composition is orally acceptable.
- Orally acceptable refers to ingredients typically used in oral care compositions, and is intended to underscore that materials that are toxic when present in the amount typically found in oral care compositions are not contemplated as part of the invention.
- the compositions of the invention may be
- polymer refers to a polymeric compound prepared by polymerizing monomers, whether of the same or a different type.
- the generic term “polymer” includes the terms “homopolymer,” “copolymer,” and “terpolymer.”
- polymerized units derived from refers to polymer molecules that are synthesized according to polymerization techniques wherein a product polymer contains “polymerized units derived from” the constituent monomers which are the starting materials for the polymerization reactions.
- (meth)acrylate refers to either acrylate or methacrylate
- (meth)acrylic refers to either acrylic or methacrylic
- phosphorus acid group refers to a phosphorus oxo acid having a POH moiety in which the hydrogen atom is ionizable. Also included in the term “phosphorus acid group” are salts of the phosphorus oxo acid. In its salt or basic form, the phosphorus acid group has a cation such as a metal ion or an ammonium ion replacing at least one acid proton. Examples of phosphorus acid groups include groups formed from phosphinic acid, phosphonic acid, phosphoric acid, pyrophosphinic acid, pyrophosphoric acid, partial esters thereof, and salts thereof.
- glass transition temperature or “T g” refers to the temperature at or above which a glassy polymer will undergo segmental motion of the polymer chain. Glass transition temperatures of a polymer can be estimated by the Fox equation ⁇ Bulletin of the American Physical Society, 1 (3) Page 123 (1956)) as follows:
- w ⁇ and w 2 refer to the weight fraction of the two comonomers
- r g(1) and r g(2) refer to the glass transition temperatures of the two corresponding homopolymers made from the monomers.
- additional terms are added ( ⁇ ⁇ /3 ⁇ 4 ⁇ )) ⁇
- the 3 ⁇ 4 of a polymer can also be calculated by using appropriate values for the glass transition temperatures of homopolymers, which may be found, for example, in "Polymer Handbook," edited by J. Brandrup and E.H. Immergut, Interscience Publishers.
- the T g of a polymer can also be measured by various techniques, including, for example, differential scanning calorimetry ("DSC"). The values of T g reported herein are measured by DSC.
- the oral care compositions of the present invention also contain copolymer particles bearing phosphorus acid groups pendant to a polymer backbone.
- the copolymer particles are dispersed in an aqueous medium, and are insoluble in the aqueous medium.
- the copolymer particles are addition polymers, which comprise polymerized units derived from (i) ethylenically unsaturated monomers having a phosphorus acid groups, referred to herein as "phosphorus acid monomers,” and (ii) ethylenically unsaturated monomers, referred to herein as "comonomers.”
- the phosphorus acid monomers contain at least one ethylenic unsaturation and a phosphorus acid group.
- the phosphorus acid monomer may be in the acid form or as a salt of the phosphorus acid group.
- Suitable phosphorus acid monomers include, for example:
- R is an organic group containing an acryloxy, methacryloxy, or a vinyl group; and R' and R" are independently selected from H and a second organic group.
- the second organic group maybe saturated or unsaturated.
- Suitable phosphorus acid monomers include, for example, dihydrogen phosphate-functional monomers, e.g., dihydrogen phosphate esters of an alcohol in which the alcohol also contains a polymerizable vinyl or olefinic group (e.g., allyl phosphate, mono- or diphosphate of bis(hydroxyl-methyl)fumarate or itaconate), and derivatives of (meth)acrylic acid esters, e.g., phosphates of hydroxyalkyl (meth)acrylates (e.g., 2- hydroxyethyl (meth)acrylate and 3-hydroxypropyl (meth)acrylates).
- dihydrogen phosphate-functional monomers e.g., dihydrogen phosphate esters of an alcohol in which the
- Suitable phosphorus acid monomers include, for example phosphonate functional monomers, e.g., vinyl phosphonic acid, allyl phosphonic acid, a-phosphonostyrene, and 2-methylacrylamido-2- methylpropanephosphonic acid.
- phosphorus functional monomers include, for example, 1,2-ethylenically unsaturated (hydroxy )phosphinylalkyl (meth)acrylate monomers, e.g., (hydroxy)phosphinylmethyl methacrylate.
- the phosphorus acid monomers comprise dihydrogen phosphate monomers, e.g., 2-phosphoethyl (meth)acrylate, 2-phosphopropyl (meth)acrylate, 3-phosphopropyl (meth)acrylate, and 3-phospho-2- hydroxypropyl (meth)acrylate.
- the inventive copolymers comprise polymerized units of phosphorus acid monomers in an amount of at least 0.1 weight %, preferably at least 0.5 weight %, and more preferably at least 1 weight %, by weight of the copolymer.
- the inventive copolymer comprise polymerized units of phosphorus acid monomers in an amount of no more than 20 weight %, preferably no more than 10 weight %, and more preferably no more than 6 weight %.
- the comonomers are ethylenically unsaturated monomers which are not phosphorus acid monomers and are copolymerizable with an ethylenically unsaturated phosphorus acid monomer.
- Suitable comonomers include, for example, styrene, butadiene, a-methyl styrene, vinyl toluene, vinyl naphthalene, ethylene, propylene, vinyl acetate, vinyl versatate, vinyl chloride, vinylidene chloride, acrylonitrile, methacrylonitrile, (meth)acrylamide, various Ci-C 4 o alkyl esters of (meth)acrylic acid (e.g., methyl (meth)acrylate, ethyl (meth)acrylate, n-butyl (meth)acrylate, 2- ethylhexyl (meth)acrylate, cyclohexyl (meth)acrylate, n-octyl
- (meth)acrylate n-dodecyl (meth)acrylate, tetradecyl (meth)acrylate, lauryl (meth)acrylate, oleyl (meth)acrylate, palmityl (meth)acrylate, and stearyl (meth)acrylate)
- other (meth)acrylates e.g., isobornyl (meth)acrylate, benzyl (meth)acrylate, phenyl (meth)acrylate, 2-bromoethyl (meth)acrylate, 2-phenylethyl (meth)acrylate, and 1-naphthyl (meth)acrylate)
- alkoxyalkyl (meth)acrylates e.g., ethoxyethyl (meth)acrylate, mono-, di-, trialkyl esters of ethylenically unsaturated di- and tricarboxylic acids and anhydrides (e.g., ethy
- the inventive copolymers comprise polymerized units of comonomers in an amount of at least 80 weight %, preferably at least 90 weight %, and more preferably at least 94 weight %, by weight of the copolymer. In certain embodiments, the inventive copolymer comprise polymerized units of comonomers in an amount of no more than 99.9 weight %, preferably no more than 99.5 weight %, and more preferably no more than 99 weight %.
- the polymer may be a crosslinked polymer, wherein a crosslinker, such as a monomer having two or more non-conjugated ethylenically unsaturated groups, is included with the copolymer components during polymerization.
- a crosslinker such as a monomer having two or more non-conjugated ethylenically unsaturated groups
- Suitable crosslinker monomers include, for example, di- or tri-allyl ethers and di- or tri-(meth)acrylyl esters of diols or polyols (e.g., trimethylolpropane diallyl ether, ethylene glycol dimethacrylate), di- or tri-allyl esters of di- or tri-acids, allyl (meth)acrylate, divinyl sulfone, triallyl phosphate, divinylaromatics (e.g., divinylbenzene).
- the inventive copolymers comprise polymerized units of crosslinker monomers in an amount of no more than 5 weight %, preferably no more than 3 weight %, more preferably no more than 2 weight %, and even more preferably no more than 1 weight %, by weight of the copolymer.
- Polymer molecular weights can be measured by standard methods such as, for example, size exclusion chromatography.
- the copolymer particles of the present invention have a weight average molecular weight (M w ) of 5,000,000 or less, 3,000,000 or less, 2,000,000 or less, or 1,000,000 or less, as measured by gel permeation chromatography.
- the copolymer particles have a M w of 5,000 or more, preferably 50,000 or more, and more preferably 100,000 or more, as measured by gel permeation chromatography.
- Copolymer particles suitable for use in the inventive oral care compositions including a two stage copolymer have T g values in the range of from 50°C to 150°C, preferably from 65°C to 100°C, and more preferably from 80°C to 90°C.
- Copolymer particles suitable for use in the inventive oral care compositions including a three stage copolymer have T g values in the range of from -5°C to 50°C, preferably from 5°C to 35°C, and more preferably from 10°C to 25°C.
- the inventive copolymer particles have an average diameter in a range of from 10 nm to 20 microns, preferably from 20 nm to 1 micron, and more preferably from 50 nm to 500 nm.
- the diameters of the copolymer particles may be characterized by distributions such as unimodal or multimodal, including bimodal.
- the average diameter of the copolymer particles may be determined by a light scattering technique.
- the inventive oral care composition includes copolymer particles in an amount of from 0.001 to 50 weight %, preferably from 0.01 to 20 weight %, and more preferably from 0.1 to 10 weight, by weight of the composition.
- Suitable polymerization techniques for preparing the copolymer particles contained in the inventive oral care compositions include, for example, emulsion polymerization, as disclosed in U.S. Patent No. 6,710,161.
- Aqueous emulsion polymerization processes typically are conducted in an aqueous reaction mixture, which contains at least one monomer and various synthesis adjuvants, such as the free radical sources, buffers, and reductants in an aqueous reaction medium.
- a chain transfer agent may be used to limit molecular weight.
- the aqueous reaction medium is the continuous fluid phase of the aqueous reaction mixture and optionally contains one or more water miscible solvents, based on the weight of the aqueous reaction medium.
- Suitable water miscible solvents include, for example, methanol, ethanol, propanol, acetone, ethylene glycol ethyl ethers, propylene glycol propyl ethers, and diacetone alcohol.
- the aqueous reaction medium contains more than 90 weight % water, preferably more than 95 weight % water, and more preferably more than 98 weight % water, based on the weight of the aqueous reaction medium.
- the polymerization process may be conducted as a batch, semicontinuous, or continuous process.
- the polymer is formed in a two stage reaction.
- the first stage comprises polymerizing 1 to 10 weight % of phosphorus acid monomers, 99 to 80 weight % comonomers, and 0 to 5 weight % of crosslinker, based on the total weight of monomers polymerized in the first stage.
- the second stage comprises polymerizing 95 to 100 weight % comonomers, and 0 to 5 weight % of crosslinker, based on the total weight of monomers polymerized in the second stage.
- the phosphorus acid monomers comprise a phosphoethyl methacrylate.
- the comonomers comprise at least one of butyl acrylate, methyl methacrylate, and methacrylic acid.
- the crosslinker comprises allyl methacrylate.
- the total ratio of monomers polymerized in stage 1 and stage 2 ranges from 97:3 to 3:97, preferably from 20:80 to 80:20, more preferably from 25:75 to 75:25, and even more preferably from 30:70 to 70:30.
- the inventive oral care compositions contain the copolymer particles dispersed in an aqueous medium.
- the aqueous medium may contain cosolvents, e.g., water miscible cosolvents.
- Suitable water miscible cosolvents include, for example, methanol, ethanol, propanol, acetone, ethylene glycol ethyl ethers, propylene glycol propyl ethers, and diacetone alcohol; and water immiscible solvents such as propyl acetate, butyl acetate, methyl isoamyl ketone, amyl acetate, diisobutyl ketone, xylene, toluene, butanol, and mineral spirits.
- the pH of the oral care composition may be in the range of 3 to 11.
- the inventive oral care composition comprise one or more fluoride salts or fluoride ion sources (i.e., fluoride salts which may be soluble).
- Suitable fluoride ion sources include, for example, stannous fluoride, sodium fluoride, potassium fluoride, potassium monofluorophosphate, sodium monofluorophosphate, ammonium monofluorophosphate, sodium fluorosilicate, ammonium fluorosilicate, amine fluoride such as olaflur (N'-ociadecySirimethykmdiamine-N,N,'-tris(2-ethanol)-dihydrofluoride), ammonium fluoride, and combinations thereof.
- the fluoride ion source includes stannous fluoride, sodium fluoride, amine fluorides, sodium monofluorophosphate, as well as mixtures thereof.
- the oral care composition of the invention may also contain a source of fluoride ions or fluorine-providing ingredient in amounts sufficient to supply 50 to 5000 ppm fluoride ion, preferably from 100 to 1000 ppm fluoride ion, and more preferably from 200 to 500 ppm fluoride ion.
- the amount of fluoride ion source effective for achieving the desired property provided by such components can be readily determined by one skilled in the art.
- the fluoride ion source is present in a range of from 0.001 to 10 weight %, preferably of from 0.003 to 5 weight %, and more preferably of from 0.01 to 1 weight %.
- Oral care compositions of the invention also include an orally acceptable carrier.
- Such material is typically characterized as a carrier or diluent that are safe for use and do not negate the activity and properties of the active agent(s) in the composition.
- Suitable orally acceptable carriers include, for example, water (such as deionized or distilled water) and various solvents that may contain a humectant including, for example, glycerin, sorbitol, xylitol, and the like.
- the composition contains from about 99.99 to about 50 percent by weight of the orally acceptable carrier, based on the total weight of the composition.
- the oral care compositions of the invention may also include other ingredients known in the art of oral care compositions and which are operably for the prevention of treatment of a condition or a disorder of hard or soft tissue of the oral cavity, the prevention or treatment of a physiological disorder or condition, or which provide a cosmetic benefit.
- Such other ingredients include, for example, anti-plaque agents, whitening agents, cleaning agents, flavoring agents, sweetening agents (e.g., sorbitol, sucralose, sodium saccharin, and xylitol), adhesion agents, surfactants, foam modulators, abrasives, pH modifying agents, humectants, mouth feel agents, colorants, abrasives (e.g., aluminum hydroxide, calcium carbonate, dicalcium phosphate, and silicas), remineralizers, hydroxyapatite, phosphates (e.g., calcium phosphate), tartar control (anti- calculus) agents, saliva stimulating agents, anti- sensitivity agents, antioxidants, nutrients, viscosity modifiers, diluents, opacifiers, breath freshening agents, zinc salts, antibacterial agents (e.g., phenol, thymol, eugenol, eucalyptol, and menthol), and combinations thereof.
- oral care compositions of the present invention are highly effective at aiding the deposition and adhesion of fluoride on teeth enamel, and also to bind to hard tissue including hydroxyapatite and enamel, thereby preventing of the erosion of calcium on teeth. Accordingly, the oral care compositions of the present invention are effective to protect the hard tissue from loss of calcium by at least 5 percent after exposure of the hydroxyapatite to the polymers for 0.1-10 minutes and subsequent exposure of the polymer coated hydroxyapatite to a 0.3-1% citric acid solution, such as for 15 minutes at 37°C, as compared to hydroxyapatite which is not bound to the copolymer particles.
- the inventive copolymer particles are effective to protect the hard tissue from loss of calcium by at least 10 percent, preferably at least 15 percent, preferably at least 20 percent, preferably at least 25 percent, preferably at least 30 percent, preferably at least 35 percent, preferably at least 40 percent, preferably at least 45 percent, preferably at least 50 percent, preferably at least 55 percent, and even more preferably at least 60 percent.
- the oral care compositions may be used in a method for protecting tooth enamel from acid erosion comprising applying to the tooth enamel an oral care composition comprising (a) 0.001 to 50 weight % copolymer particles dispersed in an aqueous medium, based on the weight of the composition, wherein the copolymer particles comprise polymerized units derived from (i) 0.1 to 20 weight % of phosphorus acid monomers, and (ii) 80 to 99.9 weight % of comonomers, and (b) a dermatologically acceptable carrier.
- the phosphorous acid monomers comprise phosphoethyl methacrylate
- the comonomers comprise at least one of butyl acrylate, methyl methacrylate, and methacrylic acid.
- the oral care compositions are generally administered via a toothpaste, mouthwash, strips, and gel containing trays which include the copolymer particles described herein.
- Regular applications of the inventive compositions are effective for providing a protective layer on tooth enamel at a first time of application, and thereafter.
- a person of ordinary skill in the art can readily determine the frequency with which the compositions should be applied. The frequency may depend, for example, on the level of exposure to foods that result in high acid levels that an individual is likely to encounter in a given day and/or the sensitivity of the individual to such high acid levels. By way of non-limiting example, administration on a frequency of at least once per day may be desirable.
- Exemplary copolymer particles in accordance with the present invention contain the components recited in Table 1.
- Stage 2 (56.5%): 45 BA / 42.2 MMA / 1 MAA / 2.9 PEM / 8.9 AAEM Stage 3 (3%): 20 BA / 74 MMA / 6 MAA
- Stage 2 (56.5%): 50 BA / 37.18 MMA / 1 MAA / 2.92 PEM / 8.9 AAEM Stage 3 (3%): 20 BA / 74 MMA / 6 MAA
- Stage 2 (65.5%): 61.1 BA / 26.18 MMA / 1 MAA / 8.8 AAEM / 2.92 PEM Stage 3 (3%): 20 BA / 74 MMA / 6 MAA
- Stage 2 (56.5%): 66 BA / 21.28 MMA / 1 MAA / 8.8 AAEM / 2.92 PEM Stage 3 (3%): 20 BA / 74 MMA / 6 MAA
- MMA methyl methacrylate
- MAA methacrylic acid
- PEM phosphoethyl methacrylate
- AAEM acetoacetoxyethyl methacrylate
- a Stage 1 monomer emulsion was prepared by mixing 65.5 g DI water, 16.5 g (30% active) anionic surfactant-A (surfactant having an average composition of lauryl- (ethylene oxide) 4 sodium sulfate; 30 wt % solids), 27.14 g BA, 202.36 g MMA, 0.50 g MAA, and 16.2 g PEM.
- a Stage 2 monomer emulsion was then prepared by mixing 136 g DI water, 15.4 g (30% active) anionic surfactant A, 64.5 g BA, 392.2 g MMA, and 0.95 g MAA.
- a 3 liter reactor, four-necked round bottom flask equipped with a paddle stirrer, a thermocouple, nitrogen inlet, and reflux condenser was assembled.
- To the flask was added 1,170 g DI water and 16.5 g (30% active) anionic surfactant A, and stirring was started.
- the contents of the flask were heated to 84°C. under a nitrogen atmosphere.
- a solution of 1.4 g NaPS in 13 g DI water was added.
- the stage 1 monomer emulsion was fed into the reactor over 40 minutes.
- a solution of 0.71 g NaPS in 43 g DI water was fed separately to the flask for 40 minutes.
- Stage 1 monomer emulsion After the addition of Stage 1 monomer emulsion the container was rinsed with a small portion of DI water and added into the flask. The NaPS co-feed was stopped and the reaction held at 87 °C for 10 minutes. The Stage 2 monomer emulsion was fed into the flask over 65 minutes. The NaPS co-feed was restarted and fed for 65 minutes. Furthermore, a separate solution containing 5.3 g of ammonium hydroxide (28% solution), 20 g of water was fed over 65 minutes. After the addition of Stage 2 monomer emulsion the container was rinsed with a small portion of DI water and fed into the flask. The contents of the flask were maintained at 84-86°C for 5 minutes. The batch was then cooled to 65°C. A redox pair of hydrogen peroxide aqueous solution and iso-ascorbic acid solution was fed into the kettle separately. The batch was cooled to room temperature.
- Polymers A and C-E were prepared substantially as described above, with the appropriate changes in monomer amounts as recited in Table 1.
- a first monomer emulsion was prepared by mixing 160.0 deionized water, 38.1 g DISPONIL FES 32 surfactant (available from BASF; 30% active), 323.6 g BA, 396.2 g MMA, and 2.9 g MAA.
- a second monomer emulsion was then prepared by mixing 272.1 g deionized water, 37.5 g DISPONIL FES 993 surfactant (available from BASF; 30% active), 29.8 g PEM, 452.7 g BA, 422.4 g MMA, 74.5 g AAEM, and 9.9 g MAA.
- a third monomer mixture was prepared by mixing 43.8 g deionized water, 10.5 g BA, 38.0 g MMA, and 4.3 g MAA.
- Deionized water (1106.3 g) and DISPONIL FES 32 surfactant (2.3 g, 30% active) were added to a 5-L, four-necked round-bottom flask equipped with a paddle stirrer, a thermometer, nitrogen inlet, and a reflux condenser. The contents of the flask were heated to 85°C under a N 2 atmosphere, and stirring was initiated. A portion of the first monomer emulsion (110.4 g) was added to the flask followed by a rinse of DI water (5.0 g). A solution of sodium persulfate (5.4 g) dissolved in deionized water (33.9 g), followed by a rinse of deionized water (6.7 g) was subsequently added to the reactor.
- the second monomer emulsion and an initiator solution containing sodium persulfate (0.99 g) dissolved in DI water (52.8 g) were added linearly and separately to the vessel over 75 min. The temperature was maintained at 85°C. The second monomer emulsion vessel was rinsed to the reactor with deionized water (27 g).
- Polymers G-I were prepared substantially as described above, with the appropriate changes in monomer amounts as recited in Table 1.
- Copolymer particles as prepared in Examples 1 and 2 above were evaluated for pH, % solids, and particle size, as show in Table 3.
- the r g was measured by DSC using a TA Instruments Q2000 DSC.
- the particle size for Samples A-E was measured using a Matex CHDF 2000, and for samples F-I using a Malvern BI
- a 250 ppm sodium fluoride solution was prepared by charging a 150 mL glass jar with 24.9mg (0.593mmol) of sodium fluoride and lOOmL of DI H 2 0. The solution was stirred for 5min or until all the solids have completely dissolved.
- Preconditioning step Each 20mL vial with disc was added with 4mL of 1% citric acid solution and was stirred at 37°C for 15min. After 15min, each discs in vials were rinsed with DI water (5 times, 20mL each time). The discs were dried in the oven (45°C) for lh. At this time, the discs are now ready for the initial acid treatment.
- Initial acid treatment Each 20mL vial with disc was added with 4mL of 1% citric acid solution and was stirred at 37°C for 15min. After 15min, the solution from each vials were transferred to a labeled 20mL vials for analytical testing.
- Each disc in vials were rinsed with 4mL DI water and the rinsed solution was added to the newly labeled vials for analytical testing. (Note: Each vials for analytical, contained 8mL of solution.)
- Samples from each of the vials was diluted 1: 100 using DI water to a volume of 50 mL and evaluated using an Agilent 7500 ICP-MS. Samples were monitored for 44 Ca and 45 Sc with integration times of 0.30 seconds per point and rinse times of 60 seconds (random samples were spiked with 0.2 ppm of Ca in solution).
- the reagent blank contained 0.5 mL of citric acid, 2 mLs of 0.1 ppm Sc, and 47.5 mL of DI water. The results of the anti-erosion study are shown below in Table 4.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Cosmetics (AREA)
Abstract
L'invention concerne des compositions de soin buccal comprenant (a) de 0,001 à 50 % en poids de particules de copolymère dispersées dans un milieu aqueux, en se basant sur le poids de la composition, les particules de copolymère comprenant des unités polymérisées dérivées à partir (i) de 0,1 à 20 % en poids de monomères d'acide phosphoreux, et (ii) de 80 à 99,9 % en poids de comonomères et (b) un excipient acceptable par voie orale. L'invention concerne également des procédés de protection de l'émail dentaire contre l'érosion acide, qui consiste à appliquer sur l'émail dentaire une composition de soins buccal comprenant de telles compositions de soin buccal.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562183359P | 2015-06-23 | 2015-06-23 | |
US62/183,359 | 2015-06-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016209881A1 true WO2016209881A1 (fr) | 2016-12-29 |
Family
ID=56297133
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2016/038644 WO2016209881A1 (fr) | 2015-06-23 | 2016-06-22 | Formulations de soin buccal contenant des copolymères |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2016209881A1 (fr) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030236374A1 (en) * | 2002-06-19 | 2003-12-25 | Bardman James Keith | Polymer composition and monomer composition for preparing thereof |
WO2007022167A1 (fr) * | 2005-08-17 | 2007-02-22 | Colgate-Palmolive Company | Inhibition de dépôt bactérien sur les surfaces orales |
US20140134116A1 (en) | 2012-11-09 | 2014-05-15 | Colgate-Palmolive Company | Block Copolymers For Tooth Enamel Protection |
WO2015094334A1 (fr) * | 2013-12-20 | 2015-06-25 | Colgate-Palmolive Company | Compositions et méthodes de soin buccal |
-
2016
- 2016-06-22 WO PCT/US2016/038644 patent/WO2016209881A1/fr active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030236374A1 (en) * | 2002-06-19 | 2003-12-25 | Bardman James Keith | Polymer composition and monomer composition for preparing thereof |
US6710161B2 (en) | 2002-06-19 | 2004-03-23 | Rohm And Haas Company | Polymer composition and monomer composition for preparing thereof |
WO2007022167A1 (fr) * | 2005-08-17 | 2007-02-22 | Colgate-Palmolive Company | Inhibition de dépôt bactérien sur les surfaces orales |
US20140134116A1 (en) | 2012-11-09 | 2014-05-15 | Colgate-Palmolive Company | Block Copolymers For Tooth Enamel Protection |
WO2014074854A1 (fr) * | 2012-11-09 | 2014-05-15 | Wang Tongxin | Copolymères à blocs pour la protection de l'émail des dents |
WO2015094334A1 (fr) * | 2013-12-20 | 2015-06-25 | Colgate-Palmolive Company | Compositions et méthodes de soin buccal |
Non-Patent Citations (2)
Title |
---|
"Polymer Handbook", INTERSCIENCE PUBLISHERS |
BULLETIN OF THE AMERICAN PHYSICAL SOCIETY, vol. 1, no. 3, 1956, pages 123 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20080299520A1 (en) | Foamable Dental Compositions and Methods | |
JP6970660B2 (ja) | スキンケア組成物 | |
US20080305457A1 (en) | Methods of Applying Dental Agents to Dental Surfaces and Polymer Compositions | |
TW200800288A (en) | Inhibition of bacterial deposition on oral surfaces | |
US20210251879A1 (en) | Block copolymers for tooth enamel protection | |
JP2018531222A6 (ja) | スキンケア組成物 | |
JP4849917B2 (ja) | 歯科用硬化性組成物 | |
JP2021505561A (ja) | ホスホネート及びアニオン性基含有ポリマーを含む口腔ケア組成物 | |
US10292914B2 (en) | Skin care formulations containing copolymers and inorganic metal oxide particles | |
JP2008285645A (ja) | 硬化性組成物 | |
JP6408683B2 (ja) | 歯科用接着性組成物 | |
JP2015067551A (ja) | 歯科用接着性組成物 | |
JP2014237593A (ja) | 歯科用接着性組成物 | |
WO2016209881A1 (fr) | Formulations de soin buccal contenant des copolymères | |
JP2007063332A (ja) | 硬化性組成物 | |
JP2018502843A (ja) | リン酸基を持つコポリマー及び無機金属酸化物粒子を含有するスキンケア製剤 | |
JP2021505612A (ja) | 口腔ケア組成物 | |
JP4098010B2 (ja) | 口腔用ポリマー | |
WO2018106666A1 (fr) | Copolymères et compositions pour soins buccaux et procédés d'utilisation | |
JP5660927B2 (ja) | 硬化性組成物 | |
CN111465431B (zh) | 口腔护理组合物 | |
JP2023056980A (ja) | 歯科用硬化性組成物 | |
JP2000191983A (ja) | 歯のコ―ティング剤組成物 | |
JP2005263678A (ja) | 歯のコーティング剤組成物 | |
JP2005200345A (ja) | 歯牙表面脱灰抑制剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16734123 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 07.05.2018) |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 16734123 Country of ref document: EP Kind code of ref document: A1 |